Men and women--similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration
- PMID: 26406297
- DOI: 10.2217/fca.15.46
Men and women--similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration
Abstract
Evaluation of: Fulcher et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976), 1397-1405 (2015). A recent publication has explored the role of gender in determining the benefit from statins. Using data on 174,000 patients (including 46,000 women) collected up to 2010, a meta-analysis was performed using individual patient data, separately analyzing results for men and women and adjusting for baseline risk and nongender related risk factors. Over a median duration of follow-up of 4.9 years, statins reduced the risk of major vascular events by 21% for each mmol/l reduction of LDL cholesterol (relative risk: 0.79; 95% CI: 0.77-0.81; p < 0.001), reducing risk by 22% for men and 16% for women. There was no significant overall heterogeneity for the benefit achieved in men versus that achieved in women after adjusting for baseline risk. Baseline risk substantially affected the absolute number of events prevented, but did not affect the proportional benefit attributed to the use of statins. Total mortality was similarly and significantly reduced in men (10%) and women (9%). This study adds to existing literature in confirming that statins have demonstrable benefit in men and women.
Keywords: HMG CoA reductase; absolute risk; atherosclerosis; cardiac; cardiovascular; cholesterol; coronary; gender; review; statin; women.
Comment on
-
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9. Lancet. 2015. PMID: 25579834
Similar articles
-
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9. Lancet. 2015. PMID: 25579834
-
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. Lancet. 2012. PMID: 22607822 Free PMC article.
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28. Lancet. 2009. PMID: 19329177 Clinical Trial.
-
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.
-
Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 21391729 Review.
Cited by
-
The effect of adherence to statin therapy on cardiovascular mortality: quantification of unmeasured bias using falsification end-points.BMC Public Health. 2016 Apr 11;16:303. doi: 10.1186/s12889-016-2986-0. BMC Public Health. 2016. PMID: 27067123 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical